Okla. Stat. tit. 63, § 63-2-803: Approved cannabidiol for use in clinical trials

A. Clinical trials conducted pursuant to a statewide

investigational new drug application established pursuant to the

provisions of this act shall only utilize cannabidiol which is:

1. From an approved source; and

2. Approved by the United States Food and Drug Administration

to be used for treatment of a condition specified in an

investigational new drug application.

B. The principal investigator and any subinvestigator may

receive cannabidiol directly from an approved source or authorized

distributor for an approved source for use in the clinical trials.